- Home
- ENTX vs PAVS Comparison
ENTX vs PAVS Comparison
Compare ENTX & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- PAVS
- Stock Information
- Founded
- ENTX 2010
- PAVS 2004
- Country
- ENTX Israel
- PAVS United States
- Employees
- ENTX N/A
- PAVS N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- ENTX Health Care
- PAVS Health Care
- Exchange
- ENTX Nasdaq
- PAVS Nasdaq
- Market Cap
- ENTX 82.2M
- PAVS 49.1M
- IPO Year
- ENTX 2018
- PAVS 2019
- Fundamental
- Price
- ENTX $1.77
- PAVS $0.85
- Analyst Decision
- ENTX Strong Buy
- PAVS
- Analyst Count
- ENTX 1
- PAVS 0
- Target Price
- ENTX $10.00
- PAVS N/A
- AVG Volume (30 Days)
- ENTX 77.8K
- PAVS 149.0K
- Earning Date
- ENTX 11-07-2025
- PAVS 08-04-2025
- Dividend Yield
- ENTX N/A
- PAVS N/A
- EPS Growth
- ENTX N/A
- PAVS N/A
- EPS
- ENTX N/A
- PAVS N/A
- Revenue
- ENTX $166,000.00
- PAVS $71,542.00
- Revenue This Year
- ENTX N/A
- PAVS N/A
- Revenue Next Year
- ENTX N/A
- PAVS N/A
- P/E Ratio
- ENTX N/A
- PAVS N/A
- Revenue Growth
- ENTX 191.23
- PAVS N/A
- 52 Week Low
- ENTX $1.50
- PAVS $0.32
- 52 Week High
- ENTX $2.79
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- ENTX 38.11
- PAVS 55.26
- Support Level
- ENTX $1.83
- PAVS $0.76
- Resistance Level
- ENTX $1.89
- PAVS $0.90
- Average True Range (ATR)
- ENTX 0.11
- PAVS 0.12
- MACD
- ENTX -0.02
- PAVS 0.01
- Stochastic Oscillator
- ENTX 0.00
- PAVS 43.18
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.